Table 2:
Characteristics of the patients according to STEMI location (anterior vs non anterior) and treatment (anakinra vs placebo)
| Anterior STEMI | Non anterior STEMI | ||||
|---|---|---|---|---|---|
| Placebo (n=17) | Anakinra (n=30) | Placebo (n=38) | Anakinra (n=54) | P value | |
| Clinical Characteristics | |||||
| Age (median, IQR) | 58 [52–63] | 54 [48–60] | 57 [50–65] | 56 [49–61] | 0.464 |
| Male (%) | 15 (88%) | 21 (70%) | 33 (87%) | 41(76%) | 0.254 |
| White (%) | 10 (59%) | 17 (58%) | 25 (66%) | 35 (65%) | 0.842 |
| BMI (median, IQR) | 29 [27–34] | 31 [25–34] | 29 [26–36] | 31 [25–34] | 0.888 |
| Diabetes mellitus (%) | 9 (53%) | 5 (17%) | 10 (26%) | 15 (28%) | 0.066 |
| Hypertension (%) | 12 (71%) | 16 (53%) | 25 (66%) | 39 (54%) | 0.442 |
| Tobacco use (%) | 10 (59%) | 21 (70%) | 19 (50%) | 30 (56%) | 0.409 |
| Dyslipidemia (%) | 7 (41%) | 15 (50%) | 18 (47%) | 31 (57%) | 0.625 |
| Previous history of CABG (%) | 1 (6%) | 0 (0%) | 1 (3%) | 4 (7%) | 0.397 |
| Chronic obstructive pulmonary disease (%) | 1 (6%) | 2 (7%) | 4 (11%) | 1 (2%) | 0.368 |
| Clinical presentation | |||||
| Thrombolysis (%) | 2 (12%) | 2 (7%) | 5 (13%) | 5 (9%) | 0.831 |
| Symptoms to balloon time (min) | 210 [99–339] | 129 [77–244] | 180 [120–377] | 203 [130–416] | 0.301 |
| Angiographic data | |||||
| TIMI flow 0/1 pre-PCI (%) | 15 (88%) | 27 (90%) | 28 (74%) | 47 (87%) | 0.218 |
| TIMI flow 3 post-PCI (%) | 16 (94%) | 29 (97%) | 37 (97%) | 51 (94%) | 0.204 |
| Coronary artery stenting (%) | 17 (100%) | 27 (90%) | 38 (100%) | 48 (89%) | 0.096 |
| Manual aspiration thrombectomy (%) | 1 (6%) | 5 (17%) | 9 (24%) | 6 (11%) | 0.831 |
| Laboratory data at baseline (median IQR) | |||||
| WBC (x103/L) | 13.9 [8.7–16.1] | 10.3 [8.4–10.3] | 10.5 [8.0–13.8] | 11.8 [9.0–14.2] | 0.070 |
| Peak CK-MB (ng/mL) | 143 [31–293] | 212 [89–260] | 94 [59–218] | 118 [40–223] | 0.360 |
| AUC-hsCRP (mg•day/L) | 310 [197–593] | 98 [42–196] | 184 [108–322] | 66 [41–138] | <0.001 |
| Echocardiographic data (median, IQR) | |||||
| LV Ejection Fraction, % at baseline | 44 [40–60] | 46 [39–52] | 54 [43–56] | 53 [45–59] | 0.035 |
| Interval change in LVEF, % | +2% [−6 to 9] | +5% [+1 to +12] | +2% [−4 to +7] | +1% [−2 to +7] | 0.229 |
| Interval changes in LVEDV, ml | +2.5 [−9 to +8] | +3 [−6 to +26] | −3.5 [−14 to +11] | +4 [−6 to +16] | 0.222 |
| Interval changes in LVESV, ml | +2 [−15; +13], | −1 [−14 to +10] | +3 [−11 to +3] | +1 [−7 to +6] | 0.665 |
| Medication at discharge | |||||
| Beta-Blockers (%) | 15 (88%) | 24 (80%) | 32 (84%) | 50 (93%) | 0.378 |
| Aspirin (%) | 17 (100%) | 30 (100%) | 38 (100%) | 53 (98%) | 0.663 |
| ACEi/ARB (%) | 14 (82%) | 26 (87%) | 33 (87%) | 43 (80%) | 0.771 |
| Statin (%) | 17 (100%) | 30 (100%) | 37 (97%) | 53 (98%) | 0.663 |
| P2Y12 inhibitors (%) | 17 (100%) | 30 (100%) | 38 (100%) | 54 (100%) | 1 |
Abbreviations: ACEi/ARB: angiotensin converting enzymes inhibitor/ angiotensin II receptor blockers; BMI: body mass index; CABG: coronary artery bypass graft; CK-MB: Creatine kinase-MB; LV: left ventricle; LVEDV: left ventricle end-diastolic volume; LVESV: left ventricle end-systolic volume; hsCRP: high sensitivity C-reactive-protein; IQR: interquartile range; SD: standard deviation; TIMI: Thrombolysis in myocardial infarction; WBC: white blood cell count